Norepinephrine Sintetica (Noradrenaline Tartrate)

Noradrenaline Tartrate acts as a direct agonist at alpha‑1 adrenergic receptors, causing vasoconstriction and increasing systemic vascular resistance. It also stimulates beta‑1 receptors in the heart, modestly enhancing contractility and heart rate, which together improve cardiac output in shock states.

The dosing regimen for Norepinephrine Sintetica is individualized by the prescribing clinician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. Dosage is typically administered as a continuous intravenous infusion that is titrated to effect.

The safety of Norepinephrine Sintetica during pregnancy or lactation has not been established, and the product carries an unknown pregnancy category. Use is generally reserved for life‑threatening situations where benefits outweigh potential risks, and it should be prescribed by a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Norepinephrine is often preferred over agents such as dopamine or phenylephrine because it provides strong alpha‑1 mediated vasoconstriction with modest beta‑1 activity, offering balanced blood‑pressure support while minimizing tachyarrhythmias. Choice of vasopressor depends on the clinical scenario and patient comorbidities.

Norepinephrine Sintetica must be stored at 2‑8 °C, protected from light, and should never be frozen or shaken. The product should be kept in its original packaging until use, and any unused portion should be discarded according to local regulations.

The medication is supplied as a sterile injectable solution for intravenous infusion. It is typically administered through a central or peripheral line using an infusion pump, with the rate adjusted continuously based on the patient’s blood‑pressure response and clinical condition.

Serious risks include severe hypertension, myocardial ischemia, tissue necrosis from extravasation, life‑threatening arrhythmias, and pulmonary edema. Continuous hemodynamic monitoring and careful infusion site inspection are essential to detect and manage these complications promptly.

Patients with known hypersensitivity to norepinephrine or its excipients should avoid the drug. Caution is also advised in individuals with severe peripheral vascular disease, uncontrolled tachyarrhythmias, or those receiving MAO inhibitors, where the risk of hypertensive crisis is heightened.